Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
June 01 2016 - 4:01PM
Business Wire
Presentations to be Webcast on June 8, at
3:30 p.m. ET and June 21 at 9:00 a.m. ET
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will make a formal company presentation, including a
business overview and an update on Enanta’s research and
development pipeline at each of the following investor
conferences:
- June 8, 3:30 p.m. ET – Jefferies 2016
Healthcare Conference, New York City
- June 21, 9:00 a.m. ET – JMP Securities
Life Sciences Conference, New York City
A live webcast and replay of each presentation will be
accessible by visiting the “Calendar of Events” section on the
“Investors” page of Enanta’s website at www.enanta.com. The replay
webcast will be available following each presentation and will be
archived for approximately 30 days.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta’s research and development efforts are currently focused on
four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus
(HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory
Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors and NS5A
inhibitors that are members of the direct-acting-antiviral (DAA)
inhibitor classes designed for use against the hepatitis C virus
(HCV). Enanta’s protease inhibitors, developed through its
collaboration with AbbVie, include paritaprevir, which is contained
in AbbVie’s marketed DAA regimens for HCV, and ABT-493, Enanta’s
second protease inhibitor, which AbbVie is developing in phase 3
studies in combination with ABT-530, AbbVie’s NS5A inhibitor.
Enanta has also discovered a cyclophilin inhibitor, EDP-494, a
novel host-targeting mechanism for HCV, which is now in phase 1
clinical development, and EDP-305, an FXR agonist, which Enanta
plans to advance into clinical development for NASH later in 2016.
Please visit www.enanta.com for more information on our programs
and pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160601005316/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024